Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nitazoxanide + peginterferon alfa-2a + ribavirin
- Development stage
- Preclinical
- Lead developer
- Romark Laboratories
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This is a **combination therapy** comprising three drugs: **nitazoxanide**, **peginterferon alfa-2a**, and **ribavirin**. - **Nitazoxanide** is a broad-spectrum antiviral and antiparasitic agent, thought to interfere with viral maturation and modulate the host immune response. - **Peginterferon alfa-2a** is a pegylated recombinant interferon used primarily as an immunomodulator, acting via activation of the interferon alpha/beta receptor and induction of antiviral proteins as part of the innate immune response. - **Ribavirin** is a nucleoside analog antiviral that inhibits viral RNA synthesis and viral mRNA capping. The combination is being investigated for the treatment of **chronic hepatitis C virus infection**, with the potential goal of improving sustained virological response rates through complementary antiviral and immunomodulatory mechanisms.
- Other names
- peginterferon alfa-2a + ribavirin + nitazoxanidePEG-IFN alfa-2a + RBV + NTZ
02
Targets
EIF2AK2 (Interferon-induced protein kinase R)IFNAR (Immune system modulation via type I interferon receptor)EIF2S1 (Eukaryotic translation initiation factor 2 alpha subunit)
Beyond the preview
Go deeper on nitazoxanide + peginterferon alfa-2a + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nitazoxanide + peginterferon alfa-2a + ribavirin.